

Axitinib AXIS

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokine

Experimental Arm: Axitinib

Control Arm: Sorafenib



